- $6.73bn
- $6.28bn
- $22.29m
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Gilead Extends Tender Offer To Acquire Arcellx
U.S. RESEARCH ROUNDUP-Arcellx, Costar Group, Magnite
Street View: Gilead's Arcellx buyout a long-term bet on cancer cell therapy
An $8 bln pharma deal prices patent fears
U.S. STOCKS ON THE MOVE-AbbVie, CrowdStrike, PayPal
An $8 bln pharma deal prices patent fears
Arcellx hits record high as Gilead agrees to up to $7.8 bln acquisition
U.S. STOCKS ON THE MOVE-Enhabit, Ethos Technologies, gold miners
U.S. STOCKS ON THE MOVE-Merck, Alphabet, JPMorgan Chase
U.S. STOCKS ON THE MOVE-Eli Lilly, Domino's, Novo Nordisk
Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion (updated)
Arcellx soars as Gilead agrees to up to $7.8 billion acquisition
Brief: Gilead Sciences To Acquire Arcellx To Maximize Long-Term Potential Of Anito-Cel
Gilead to acquire Arcellx for $7.8 billion (updated)
Arcellx soars after Gilead to acquire co for $7.8 billion
Gilead to acquire Arcellx for $7.8 billion
Citi sees momentum in US pharma and biotech into 2026, updates ratings on top picks